Integer (NYSE:ITGR) Price Target Raised to $154.00 at KeyCorp

Integer (NYSE:ITGR) had its price objective upped by equities research analysts at KeyCorp from $144.00 to $154.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has an “overweight” rating on the medical equipment provider’s stock. KeyCorp’s price objective would indicate a potential upside of 7.56% from the stock’s current price.

A number of other research firms also recently weighed in on ITGR. Truist Financial upped their target price on shares of Integer from $147.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Citigroup raised their price objective on Integer from $130.00 to $145.00 and gave the company a “neutral” rating in a research report on Wednesday, December 11th. Wells Fargo & Company reiterated an “overweight” rating and issued a $160.00 target price on shares of Integer in a research note on Tuesday, December 3rd. Benchmark boosted their target price on Integer from $130.00 to $140.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Finally, Piper Sandler reissued an “overweight” rating and set a $140.00 price target (up from $125.00) on shares of Integer in a report on Friday, October 25th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $146.56.

Integer Trading Down 0.1 %

NYSE ITGR traded down $0.10 during trading on Friday, hitting $143.18. The company had a trading volume of 57,034 shares, compared to its average volume of 188,065. The company’s fifty day moving average is $136.76 and its 200-day moving average is $129.33. The company has a market cap of $4.80 billion, a price-to-earnings ratio of 44.20, a price-to-earnings-growth ratio of 1.80 and a beta of 1.12. The company has a current ratio of 3.28, a quick ratio of 2.09 and a debt-to-equity ratio of 0.67. Integer has a one year low of $94.56 and a one year high of $144.22.

Integer (NYSE:ITGR) last released its earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 EPS for the quarter, beating analysts’ consensus estimates of $1.36 by $0.07. The company had revenue of $431.42 million during the quarter, compared to analysts’ expectations of $440.59 million. Integer had a return on equity of 11.63% and a net margin of 6.70%. The firm’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.27 EPS. On average, sell-side analysts predict that Integer will post 5.33 earnings per share for the current year.

Institutional Trading of Integer

Hedge funds and other institutional investors have recently made changes to their positions in the business. Driehaus Capital Management LLC raised its stake in shares of Integer by 62.5% during the 2nd quarter. Driehaus Capital Management LLC now owns 353,052 shares of the medical equipment provider’s stock valued at $40,880,000 after buying an additional 135,750 shares during the last quarter. Eagle Asset Management Inc. purchased a new position in Integer during the third quarter valued at approximately $14,403,000. Laurus Investment Counsel Inc. acquired a new position in Integer in the fourth quarter valued at approximately $5,422,000. Bamco Inc. NY boosted its position in Integer by 17.4% in the 3rd quarter. Bamco Inc. NY now owns 254,377 shares of the medical equipment provider’s stock worth $33,069,000 after purchasing an additional 37,700 shares in the last quarter. Finally, Jane Street Group LLC boosted its position in Integer by 23.3% in the 3rd quarter. Jane Street Group LLC now owns 151,397 shares of the medical equipment provider’s stock worth $19,682,000 after purchasing an additional 28,572 shares in the last quarter. Institutional investors and hedge funds own 99.29% of the company’s stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.